Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD22 CAR-T (humanized m791 4-1BB)
- Development stage
- Unknown
- Lead developer
- Stanford University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD22 CAR-T (humanized m791 4-1BB) is an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target the CD22 antigen, which is highly expressed on B-cell malignancies. The construct utilizes a humanized m791 single-chain variable fragment (scFv) for antigen recognition, coupled with a 4-1BB (CD137) costimulatory domain and a CD3-zeta signaling domain. This specific architecture is intended to enhance T-cell persistence and metabolic fitness compared to CD28-based CARs. Developed through collaboration between the National Cancer Institute and Stanford University, it is currently being evaluated in Phase I clinical trials for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), often as part of a sequential infusion regimen following CD19-targeted CAR-T therapy to mitigate the risk of relapse due to CD19 antigen loss.
- Other names
- humanized m791 4-1BB CD22 CAR-T
02
Targets
CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CD22 CAR-T (humanized m791 4-1BB).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD22 CAR-T (humanized m791 4-1BB).